BIIB Goes Bye-Bye
Biogen is having a bad day. The investors (the new ones anyway) are feeling the reeling pain of investing into biotech names. This is the truth of reward to risk. When you play in high-beta names as an investor, unfortunately, this can be an outcome. Biogen (Ticker: BIIB) is discontinuing their Alzheimer drug trial. During […]
Read Article